Events

GapSummit 2022 w/ Dr Dave Michalovich

Dave will be speaking on the “The Quantified Self Panel”, which aims to generate interesting and engaging discussions covering topics such as; 

  • How to deal with, communicate, and successfully utilise large datasets efficiently to advance healthcare research?
  • How can we benefit from digital technologies in precision healthcare, and what are the pitfalls that need addressing?
  • How do we harmonise big data with the definitions of clinical phenotypes and diagnosis?
  • How do we ensure equitable access to genomics-based technologies?
  • What impact on innovation would you most like to see, or are most excited about, regarding multi-omics datasets? 
Speakers on the panel include:
  • Prof Sir Mark Caulfield - VP for Health, Queen Mary University of London
  • Robert W Kotchie -President, Real World Solutions, IQVIA
  • Sir Harpal Kumar - President, BioPharma Business & Europe GRAIL, LLC
  • Dr Dave Michalovich - SVP Precision Medicine, BenevolentAI
  • Leanne Summers - Head of AI Strategy, NHS Transformation Directorate
Event website →


Dave Michalovich

VP Precision Medicine

Dave is responsible for driving the Precision Medicine strategy at BenevolentAI, taking a patient-centric approach to understand disease endotypes, mechanisms and targets. Prior to joining BenevolentAI Dave was a Senior Scientific Director at GSK where he led discovery teams in the Adaptive Immunity Research Unit and Respiratory TA.

More Posts

You Might Also Like

Video
Data & Digital Innovation for Climate & Health
Joanna Shields, CEO BenevolentAI, joined the Wellcome Trust Panel at the World Economic forum to discuss opportunities for data and digital innovation to impact positively climate and health.
Jan 26, 2023
News
BenevolentAI submits CTA for BEN-8744, an oral PDE10 inhibitor, as a first-in-class treatment for ulcerative colitis
BenevolentAI submits clinical trial application for BEN-8744, with a Phase I clinical trial planned for H1 2023.
Dec 21, 2022
News
BenevolentAI to present at 41st Annual J.P. Morgan Healthcare Conference
BenevolentAI ​​(Euronext Amsterdam: BAI), a leading clinical-stage AI drug discovery company, announces that it will participate in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, US from 9-12 January 2023.
Dec 1, 2022
Blog
FAIR Data Foundation: An Enabler for AI Drug Discovery
Biomedical data used in AI-enabled drug discovery should adhere to the FAIR Data Principles — Findability, Accessibility, Interoperability and Reusability. This blog explains why this is, how one can make data FAIR and challenges that remain.
Nov 8, 2022
News
BenevolentAI to present at Jefferies Investor Conference in November
BenevolentAI’s Investor Relations and Business Development team will be attending the Jefferies Healthcare London conference, with Nick Keher, CFO, presenting on Thursday 17th November.
Nov 4, 2022
News
BenevolentAI achieves further milestones in AI-enabled target identification collaboration with AstraZeneca
Two additional AI-generated novel targets selected by AstraZeneca for its drug development portfolio, resulting in two milestone payments for BenevolentAI.
Oct 6, 2022